Characteristics analysis of hepatitis B core-related antigen in children with hepatitis B e antigen-positive chronic viral hepatitis B infection.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
The objective of antiviral therapy for chronic viral hepatitis B infection (CHB) is to achieve a functional cure. An important viral marker in the serum of patients with CHB is the serum hepatitis B core-related antigen (HBcrAg). However, there is limited research on HBcrAg in juvenile patients with CHB. In this study, we aimed to investigate the correlation between serum HBcrAg and other hepatitis B virus (HBV) markers in children with CHB and its predictive significance for prognosis during antiviral therapy. A single-center retrospective study was conducted involving 79 children with CHB, aged between 0 and 16 years. All the children were treated with interferon [or combined nucleos(t)ide analogs] for 48 weeks. HBcrAg, hepatitis B surface antigen (HBsAg), and HBV DNA were measured before treatment, and at 12 and 48 weeks after treatment. The enrolled children were classified into the seroclearance group and the nonseroclearance group based on the therapeutic outcome. HBsAg seroclearance was observed in 28 out of 79 patients and hepatitis B e antigen seroconversion without HBsAg seroclearance was observed in 14 out of 79 patients following the conclusion of the treatment, with baseline HBcrAg titer levels showing no statistical significance in both the seroclearance and nonseroclearance groups (P = 0.277). HBsAg and HBV DNA were positively correlated with HBcrAg in children with CHB (R2 = 0.3289, 0.4388). The area under the receiver operating characteristic curve of the decrease in HBcrAg at 12 weeks of treatment as a predictor of seroclearance at 48 weeks of treatment, exhibited a value of 0.77. A decrease in serum HBcrAg levels in children with hepatitis B serves as a prognostic indicator.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of antiviral therapy for chronic viral hepatitis B infection (CHB) is to achieve a functional cure. An important viral marker in the serum of patients with CHB is the serum hepatitis B core-related antigen (HBcrAg). However, there is limited research on HBcrAg in juvenile patients with CHB. In this study, we aimed to investigate the correlation between serum HBcrAg and other hepatitis B virus (HBV) markers in children with CHB and its predictive significance for prognosis during antiviral therapy.
METHODS
METHODS
A single-center retrospective study was conducted involving 79 children with CHB, aged between 0 and 16 years. All the children were treated with interferon [or combined nucleos(t)ide analogs] for 48 weeks. HBcrAg, hepatitis B surface antigen (HBsAg), and HBV DNA were measured before treatment, and at 12 and 48 weeks after treatment. The enrolled children were classified into the seroclearance group and the nonseroclearance group based on the therapeutic outcome.
RESULTS
RESULTS
HBsAg seroclearance was observed in 28 out of 79 patients and hepatitis B e antigen seroconversion without HBsAg seroclearance was observed in 14 out of 79 patients following the conclusion of the treatment, with baseline HBcrAg titer levels showing no statistical significance in both the seroclearance and nonseroclearance groups (P = 0.277). HBsAg and HBV DNA were positively correlated with HBcrAg in children with CHB (R2 = 0.3289, 0.4388). The area under the receiver operating characteristic curve of the decrease in HBcrAg at 12 weeks of treatment as a predictor of seroclearance at 48 weeks of treatment, exhibited a value of 0.77.
CONCLUSION
CONCLUSIONS
A decrease in serum HBcrAg levels in children with hepatitis B serves as a prognostic indicator.
Identifiants
pubmed: 38973529
doi: 10.1097/MEG.0000000000002812
pii: 00042737-990000000-00377
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Capital Clinical Characteristics Application Research: Study on Optimal treatment of copper emission in children with hepatolenticular degeneration
ID : Z181100001718030
Organisme : Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application Project Z201100005520048: Research on Optimal Program for Functional Cure of Chronic Hepatitis B in Children aged 1 to 6 years Old
ID : 2020.3-2024.03
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.
Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ 2019; 97:230–238.
Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: a pilot open-label randomized study. J Hepatol 2018; 68:1123–1128.
Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther 2018; 47:43–54.
Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precure protein without C-terminal arginine-rich domain. J Biol Chem 2005; 280:21713–21719.
Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81:27–33.
Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, et al. Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma. J Med Virol 2016; 88:244–251.
Wong DK, Yuen MF, Yuan H, Sum SS, Hui C-K, Hall J, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40:727–737.
Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70:615–625.
Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, et al. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat 2021; 28:1554–1562.
Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, et al. Interferon alpha treatment leads to a high rate of hepatitis b surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019; 26:77–84.
Hu Y, Ye Y, Ye L, Wang X, Yu H. Efficacy and safety of interferon alpha therapy in children with chronic hepatitis b: a long-term follow-up cohort study from China. Medicine (Baltimore) 2019; 98:e16683.
Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40:439–445.
Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 2021; 75:302–310.
Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016; 36:827–836.
Matsumoto A, Yatsuhashi H, Nagaoka S, Suzuki Y, Hosaka T, Tsuge M, et al. Factors associated with the effect of interferon-alpha sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2015; 45:1195–1202.
Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 2014; 20:1173–1180.
Okanoue T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, et al. Long-term follow up of peginterferon-a-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatol Res 2016; 46:992–1001.
Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010; 25:1498–1506.
Seto WK, Tanaka Y, Wong DK, Lai C-L, Shinkai N, Yuen JC, et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 2012; 7:98–105.
Cornberg M, Lok AS, Terrault NA, Zoulim F; the 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. The 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2020; 71:1070–1092.
Song G, Yang R, Rao H, Feng B, Ma H, Jin Q, et al. Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol 2017; 89:463–468.
Bae SK, Yatsuhashi H, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, et al. Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver. Med Sci Monit 2012; 18:CR698–CR705.
Wong DK, Seto WK, Cheung KS, Chong C-K, Huang F-Y, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017; 37:995–1001.
Chen EQ, Wang ML, Tao YC, Wu DB, Liao J, He M, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat 2019; 26:586–595.